Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Orthopedics · Autosomal Dominant Osteopetrosis Type II

Protecting Your Mobility: Treatment and Management Strategy

At a Glance

Managing Albers-Schönberg disease (ADO II) focuses on preventing complications since there is no cure. Key strategies include using specialized plates for fracture repair, maintaining rigorous dental hygiene to prevent severe jaw infections, and strictly avoiding standard osteoporosis medications.

Managing Albers-Schönberg disease (ADO II) requires a shift in how you and your doctors think about bone health. Because there is currently no cure, the goal is to protect your mobility and prevent complications before they start [1][2]. This involves a “defense-first” strategy, particularly when it comes to surgery and dental care.

The Emergency Action Plan: The Orthopedic Challenge

Fractures are usually sudden emergencies. If you break your leg, you will likely end up in a local ER, not with your hand-picked specialist. It is critical to inform the ER team that your bones are sclerotic (unusually hard) because treating ADO II fractures presents major technical hurdles:

  • Drilling and Hardware: Standard surgical drills can overheat or break when trying to penetrate your dense bone [3][4]. Surgeons must use specialized bits or proceed very slowly.
  • No Medullary Canal: Most modern long-bone fracture repairs involve placing a rod down the center of the bone (the medullary canal). In ADO II, this canal is often completely filled with solid bone [3][5]. Instead of drilling out the canal, surgeons frequently opt for external plates and screws to fix the break [5].
  • Healing and Failure: Because your bone remodeling is impaired, fractures take much longer to heal (delayed union) [3]. The hardware may fail before the bone is strong enough to support itself [6][7].

Your Action Plan: Carry a Wallet Emergency Card that states: “I have Autosomal Dominant Osteopetrosis Type II (Albers-Schönberg disease). My bones are extremely dense and brittle. Standard surgical drills may break, and my medullary canal may be obliterated. Intramedullary nailing is often contraindicated; please consider plates/screws and consult an academic orthopedic trauma specialist immediately.”

Dental Hygiene: Your Best Defense

Preventing jaw osteomyelitis (bone infection) is perhaps the most critical part of your daily management [8][9].

  • The Goal is Retention: You want to keep your natural teeth as long as possible. Extractions or invasive oral surgeries are high-risk events because the dense bone has a poor blood supply and cannot heal easily [10][11].
  • Rigorous Care: This means professional cleanings every 3–6 months, flawless brushing and flossing, and addressing even tiny cavities immediately [11][10].
  • Medical Alert Letter: Ask your specialist for a formal letter to keep on file with your dentist. It should warn against routine extractions without specialized protocols (such as specialized antibiotics or hyperbaric oxygen therapy) [12][13].

Why Typical Bone Drugs Will Harm, Not Help

Most medications used for osteoporosis, such as bisphosphonates (e.g., Fosamax) or denosumab (Prolia), work by slowing down osteoclasts (the cells that dissolve bone) [14].

In ADO II, your osteoclasts are already broken [15]. Taking these drugs can severely worsen your condition by shutting down whatever minimal remodeling your body is still doing. This dramatically increases the risk of “atypical” fractures and Medication-Related Osteonecrosis of the Jaw (MRONJ) [16][17][18]. Ensure your medical chart clearly lists these drugs as contraindicated. Always consult an endocrinologist who understands rare bone diseases before starting any bone-modifying medication.

Looking Toward the Future

While current management focuses on symptoms, research into the root cause of ADO II is active. Scientists are exploring siRNA therapy—a way to “silence” the mutated gene so that the healthy copy can work more effectively [19]. While these treatments are still in the experimental stages and not yet available for general use, they represent a significant step toward a future where we might treat the biology of ADO II rather than just its complications [19].

Common questions in this guide

Why is surgery difficult for ADO II fractures?
ADO II causes extremely dense and hard bones that can overheat or break standard surgical drills. Additionally, the center canal of the bone is often completely filled with bone, meaning surgeons usually must use specialized drill bits and external plates rather than standard internal rods.
Should I take standard osteoporosis medications for Albers-Schönberg disease?
No, common osteoporosis medications like bisphosphonates or denosumab are usually strictly contraindicated. In ADO II, your bone-dissolving cells are already malfunctioning. Taking these drugs further shuts down bone remodeling and severely increases the risk of atypical fractures and jaw tissue death.
Why is rigorous dental care so important if I have ADO II?
Excellent dental hygiene is crucial to prevent jaw osteomyelitis, a severe bone infection. Because the abnormally dense jawbone has a poor blood supply, routine tooth extractions or untreated cavities can lead to painful infections that your body struggles to heal.
How long do fractures take to heal with ADO II?
Fractures often take much longer to knit back together, a complication known as delayed union. This slow healing occurs because the disease impairs your normal bone remodeling process, which also means surgical hardware might fail before the bone is strong enough to support itself.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.If I break a bone and end up in the ER, what specific instructions or terminology should I give the on-call trauma surgeon?
  2. 2.Since standard osteoporosis medications like bisphosphonates can further impair osteoclasts, can you document in my chart that these are strictly contraindicated?
  3. 3.Can you write a letter for me to give to my dentist explaining the high risk of osteomyelitis and the need to avoid routine extractions?
  4. 4.If I need surgery, what specialized equipment or implants do you plan to use to handle my 'hard' bone, and do you prefer external plates over intramedullary rods?
  5. 5.What is our plan for monitoring fracture healing, given that my bones may take much longer to knit back together?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Natural History of Type II Autosomal Dominant Osteopetrosis: A Single Center Retrospective Study.

    Wang Z, Li X, Wang Y, et al.

    Frontiers in endocrinology 2022; (13()):819641 doi:10.3389/fendo.2022.819641.

    PMID: 35370969
  2. 2

    Paediatric bilateral femoral neck fractures in osteopetrosis treated conservatively.

    Kumar S, Dhammi IK, Shahi P, Zafar A

    BMJ case reports 2020; (13(12)) doi:10.1136/bcr-2020-236891.

    PMID: 33318240
  3. 3

    Subtrochanteric Femur Fracture in Osteopetrosis With Multiple Previous Fractures: A Case Report on Surgical Challenges and Outcome.

    Bist O, Dahal S, Khati S, et al.

    Clinical case reports 2025; (13(10)):e71203 doi:10.1002/ccr3.71203.

    PMID: 41079797
  4. 4

    Anterior cruciate ligament rupture in a patient with Albers-Schonberg disease.

    Lu K, Cheng B, Shi Q, et al.

    BMC musculoskeletal disorders 2022; (23(1)):719 doi:10.1186/s12891-022-05687-x.

    PMID: 35902893
  5. 5

    Intramedullary nailing for subtrochanteric fracture in autosomal dominant Type II osteopetrosis: Case report of 2 patients.

    Kim J, Park YC, Moon HS, et al.

    Medicine 2020; (99(32)):e21648 doi:10.1097/MD.0000000000021648.

    PMID: 32769934
  6. 6

    Locking plate osteosynthesis for a femoral fracture and subsequent nonunion in a patient with osteopetrosis.

    Matsuo T, Lee SY, Iwakura T, et al.

    International journal of surgery case reports 2018; (51()):395-399 doi:10.1016/j.ijscr.2018.09.013.

    PMID: 30273906
  7. 7

    A cross-sectional nationwide survey of osteosclerotic skeletal dysplasias in Japan.

    Sawamura K, Mishima K, Matsushita M, et al.

    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 2022; (27(5)):1139-1142 doi:10.1016/j.jos.2021.05.012.

    PMID: 34275722
  8. 8

    Prosthetic Management of Albers-Schönberg Disease with Osteomyelitis: A 10-Year Follow-up Case Report.

    Millet C, Ducret M, Lafon A

    The International journal of prosthodontics 2023; (36(5)):642-648 doi:10.11607/ijp.8255.

    PMID: 36484669
  9. 9

    Benign Adult-Type Osteopetrosis with Recurrent Osteomyelitis of the Maxilla-A Rare Case Report.

    Aswath N, Bhargavi R

    Indian journal of dental research : official publication of Indian Society for Dental Research 2024; doi:10.4103/ijdr.ijdr_10_24.

    PMID: 39787465
  10. 10

    Management of Osteomyelitis in Autosomal Dominant Osteopetrosis: A Rare Case Report.

    Almutairi M, Alharbi A, Almutairi H, et al.

    Cureus 2024; (16(6)):e62660 doi:10.7759/cureus.62660.

    PMID: 39036270
  11. 11

    Case report of osteomyelitis of the mandible in osteopetrosis and management considerations.

    Allal S, Rabuel V, Gengler C, et al.

    International journal of surgery case reports 2021; (81()):105813 doi:10.1016/j.ijscr.2021.105813.

    PMID: 33887866
  12. 12

    Clinical Characteristics and Treatment of Osteopetrosis Complicated by Osteomyelitis of the Mandible.

    Sun HJ, Xue L, Wu CB, Zhou Q

    The Journal of craniofacial surgery 2016; (27(8)):e728-e730 doi:10.1097/SCS.0000000000003048.

    PMID: 28005799
  13. 13

    Osteopetrosis and related osteoclast disorders in adults: A review and knowledge gaps On behalf of the European calcified tissue society and ERN BOND.

    Funck-Brentano T, Zillikens MC, Clunie G, et al.

    European journal of medical genetics 2024; (69()):104936 doi:10.1016/j.ejmg.2024.104936.

    PMID: 38593953
  14. 14

    Ocular adverse effects of bisphosphonates and association with osteonecrosis from a real-world database.

    Kim SH, Rahimy E, Koo EB, et al.

    Eye (London, England) 2026; (40(4)):534-539 doi:10.1038/s41433-025-04185-3.

    PMID: 41454062
  15. 15

    Clinical and genetic diagnosis of autosomal dominant osteopetrosis type II in a Chinese family: A case report.

    Gong HP, Ren Y, Zha PP, et al.

    World journal of clinical cases 2023; (11(3)):700-708 doi:10.12998/wjcc.v11.i3.700.

    PMID: 36793634
  16. 16

    Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.

    Nicolatou-Galitis O, Schiødt M, Mendes RA, et al.

    Oral surgery, oral medicine, oral pathology and oral radiology 2019; (127(2)):117-135 doi:10.1016/j.oooo.2018.09.008.

    PMID: 30393090
  17. 17

    The limitations of today's clinical guidance: Atypical femoral fracture and long-term bone-modifying agents in the oncology setting.

    Cheung E, Borno HT

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2020; (26(5)):1180-1189 doi:10.1177/1078155220907965.

    PMID: 32122232
  18. 18

    Atypical femoral fracture in a metastatic bone disease patient six months after discontinuation of denosumab received sequentially to previous bisphosphonate therapy - A case report.

    Georgiadis GF, Balanika AP, Vasilakis AΕ, et al.

    Journal of musculoskeletal & neuronal interactions 2021; (21(3)):429-433.

    PMID: 34465683
  19. 19

    Development and evaluation of siRNA-mediated gene silencing strategies for ADO2 therapy utilizing iPSCs model and DMPC-SPIONs delivery system.

    Xu J, Chen G, Mo C, et al.

    Stem cell research & therapy 2025; (16(1)):66 doi:10.1186/s13287-025-04151-6.

    PMID: 39934917

This page provides management and treatment strategies for ADO II for educational purposes only. Always consult an orthopedic specialist or endocrinologist before making decisions about surgeries or bone-modifying medications.

Get notified when new evidence is published on Albers-Schönberg osteopetrosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.